 |
| Preeclampsia Diagnostics Market |
The global Preeclampsia Diagnostics Market is estimated to be valued at US$ 1587.53 Mn in 2023 and is expected to exhibit a CAGR of 11.% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
Preeclampsia diagnostics include tests and devices used for the detection of
preeclampsia during pregnancy. These diagnostics help detect the condition at
an early stage and enable timely treatment. Some commonly used diagnostics are
protein urine tests, blood pressure monitors, ultrasound equipment, and Doppler
fetal monitors.
Market key trends:
The rise in adoption of non-invasive prenatal testing (NIPT) is a key trend in
the preeclampsia diagnostics market. NIPT analyzes cell-free DNA from a blood
sample of a pregnant woman to screen for chromosomal abnormalities in the
fetus, such as trisomy 13, 18, and 21. It can also detect chances of
preeclampsia in early pregnancy by analyzing placental-specific mRNA in the
mother's blood. This offers an effective alternative to invasive diagnostic
procedures like amniocentesis. The non-invasive nature and high accuracy of
NIPT have significantly increased its demand in recent years.
Here is the segment analysis and key takeaways for the given Preeclampsia
Diagnostics Market:
Segment Analysis
The preeclampsia diagnostics market is segmented by product type, test type and
end user. By product type, consumables accounted for the largest market share
in 2022. This is due to the recurring requirement of consumables such as
antibodies, proteins etc. for testing. By test type, protein urine tests
dominated the market in 2022. This segment is expected to continue its
dominance over the forecast period owing to its ability to detect protein in
urine, which is one of the early signs of preeclampsia. Hospitals represented
the largest end user segment in 2022 due to high volume of preeclampsia testing
carried out in hospitals.
Key Takeaways
The global Preeclampsia
Diagnostics Market is expected to witness high growth, exhibiting a CAGR of 11% over the forecast period,
due to increasing incidence of preeclampsia among pregnant women worldwide.
Regional Analysis
North America accounted for the largest market share in 2022 owing to presence
of major players and advanced healthcare infrastructure in the region. Asia
Pacific is expected to grow at the fastest pace during the forecast period,
attributed to rising healthcare spending, increasing awareness about
preeclampsia diagnostics and growing number of pregnancies in countries like
India and China.
Key Players
Key players operating in the preeclampsia diagnostics market are Diabetomics,
Inc., Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd, PerkinElmer
Inc., Siemens Healthineers AG, DRG INSTRUMENTS GMBH, Metabolomic Diagnostics
Ltd., Sera Prognostics, MOMM Diagnostics, Miraculins Inc. Thermo Fisher
Scientific Inc. and F. Hoffmann-La Roche Ltd captured significant market share
due to their diverse product portfolio and strong global presence.
Read More,
https://www.insightprobing.com/preeclampsia-diagnostics-market-trends-size-and-share-analysis/
0 Comments